Cambridge-based drug discovery firm sets sights on North American growth
Domainex, a leading provider of drug discovery services, is making a strategic push into the US market with the launch of two new offices in Boston, Massachusetts, and San Diego, California.
This expansion marks a significant milestone for the Chesterford Research Park-based company, which was recently recognized by the Financial Times as the fastest-growing business of its kind in Europe. With a focus on expanding its client base, Domainex has established a dedicated US business development team to strengthen its presence in two of America’s most dynamic life science hubs.
“Establishing operations in the Boston and San Diego bioclusters was a natural step,” said Trevor Perrior, Chief Scientific Officer at Domainex. “These regions share the same spirit of innovation that defines our medicines discovery centre in Cambridge. We’re excited to collaborate with forward-thinking life science organisations in North America and deliver strong returns on their R&D investments by giving them access to our multidisciplinary expertise.”
To lead the charge, Domainex has appointed two seasoned professionals to drive its business development efforts across the US. Michael Nyman, based in San Diego, brings over two decades of experience in industrial chemistry and international business development, including roles at COR Therapeutics, Bristol Myers Squibb, and Syngene. Trained as a chemist, Nyman’s background spans radiochemistry, pilot plant manufacturing, automated synthesis, and medicinal chemistry.
On the East Coast, Josephine Crespo will head the Boston office. With more than 17 years of experience in commercial roles across the pharma and biotech sectors, Crespo has represented leading companies such as Bio-Rad, Sigma-Aldrich, BioScale, and Molecular Devices. She brings a biology background and deep knowledge of delivering innovative tools and technologies to scientific markets.
“We’re thrilled to welcome Michael and Josephine to the team,” said Tom Mander, CEO of Domainex. “They each bring proven track records and valuable networks to help accelerate our growth in the US. Domainex has already partnered with top-tier pharma companies, emerging biotechs, and patient-focused organisations across North America. These new appointments and offices will enable us to serve a wider range of clients and extend our cutting-edge capabilities even further.”
Domainex’s Cambridge headquarters will remain the centre of its scientific operations as the company continues to build global momentum in the life sciences sector.
